TY - JOUR
T1 - Selexipag in the treatment of pulmonary arterial hypertension
T2 - Design, development, and therapy
AU - Hardin, Elizabeth Ashley
AU - Chin, Kelly M.
N1 - Publisher Copyright:
© 2016 Hardin and Chin.
PY - 2016/11/15
Y1 - 2016/11/15
N2 - Pulmonary arterial hypertension is characterized by abnormalities in the small pulmonary arteries including increased vasoconstriction, vascular remodeling, proliferation of smooth muscle cells, and in situ thrombosis. Selexipag, a novel, oral prostacyclin receptor agonist, has been shown to improve hemodynamics in a phase II clinical trial and reduce clinical worsening in a large phase III clinical trial involving patients with pulmonary arterial hypertension. In this paper, we describe the prostacyclin signaling pathway, currently available oral prostanoid medications, and the development and clinical use of selexipag.
AB - Pulmonary arterial hypertension is characterized by abnormalities in the small pulmonary arteries including increased vasoconstriction, vascular remodeling, proliferation of smooth muscle cells, and in situ thrombosis. Selexipag, a novel, oral prostacyclin receptor agonist, has been shown to improve hemodynamics in a phase II clinical trial and reduce clinical worsening in a large phase III clinical trial involving patients with pulmonary arterial hypertension. In this paper, we describe the prostacyclin signaling pathway, currently available oral prostanoid medications, and the development and clinical use of selexipag.
KW - Prostacyclin
KW - Pulmonary arterial hypertension
KW - Selexipag
UR - http://www.scopus.com/inward/record.url?scp=85003510877&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85003510877&partnerID=8YFLogxK
U2 - 10.2147/DDDT.S103534
DO - 10.2147/DDDT.S103534
M3 - Review article
C2 - 27895464
AN - SCOPUS:85003510877
SN - 1177-8881
VL - 10
SP - 3747
EP - 3754
JO - Drug Design, Development and Therapy
JF - Drug Design, Development and Therapy
ER -